



Article

A Glimpse into the Structural Properties of the Intermediate and Transition State in the Folding of Bromodomain 2 Domain 2 by Φ Value Analysis

Leonore Novak^{1,†}, Maria Petrosino^{1,†} , Daniele Santorelli^{1,†}, Roberta Chiaraluce¹ , Valerio Consalvi¹,
Alessandra Pasquo² and Carlo Travaglini-Allocatelli^{1,*}

¹ Dipartimento di Scienze Biochimiche “A. Rossi Fanelli”, Sapienza University of Rome, 00185 Roma, Italy; leonore.novak@uniroma1.it (L.N.); maria.petrosino@uniroma1.it (M.P.); daniele.santorelli@uniroma1.it (D.S.); roberta.chiaraluce@uniroma1.it (R.C.); valerio.consalvi@uniroma1.it (V.C.)

² ENEA CR Frascati, Diagnostics and Metrology Laboratory FSN-TECFIS-DIM, 00044 Roma, Italy; alessandra.pasquo@enea.it

* Correspondence: carlo.travaglini@uniroma1.it

† These authors contributed equally to this work.

Abstract: Bromodomains (BRDs) are small protein interaction modules of about 110 amino acids that selectively recognize acetylated lysine in histones and other proteins. These domains have been identified in a variety of multi-domain proteins involved in transcriptional regulation or chromatin remodeling in eukaryotic cells. BRD inhibition is considered an attractive therapeutic approach in epigenetic disorders, particularly in oncology. Here, we present a Φ value analysis to investigate the folding pathway of the second domain of BRD2 (BRD2(2)). Using an extensive mutational analysis based on 25 site-directed mutants, we provide structural information on both the intermediate and late transition state of BRD2(2). The data reveal that the C-terminal region represents part of the initial folding nucleus, while the N-terminal region of the domain consolidates its structure only later in the folding process. Furthermore, only a small number of native-like interactions have been identified, suggesting the presence of a non-compact, partially folded state with scarce native-like characteristics. Taken together, these results indicate that, in BRD2(2), a hierarchical mechanism of protein folding can be described with non-native interactions that play a significant role in folding.

Keywords: bromodomain; protein folding; Φ value analysis; protein stability; mutagenesis; folding kinetics



Citation: Novak, L.; Petrosino, M.; Santorelli, D.; Chiaraluce, R.; Consalvi, V.; Pasquo, A.; Travaglini-Allocatelli, C. A Glimpse into the Structural Properties of the Intermediate and Transition State in the Folding of Bromodomain 2 Domain 2 by Φ Value Analysis. *Int. J. Mol. Sci.* **2021**, *22*, 5953. <https://doi.org/10.3390/ijms22115953>

Academic Editor: Yuri Lyubchenko

Received: 3 May 2021

Accepted: 27 May 2021

Published: 31 May 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

The correct folding process of the biological macromolecules is crucial for living cells, as their biochemical processes rely on finely tuned inter-molecular recognition events, which depend on structural complementarity between interacting molecules. This biochemical principle, known as the structure–function relationship, is particularly evident in the case of structurally complex macromolecules, such as proteins. However, notwithstanding decades of experimental, theoretical, and computational efforts, the mechanism of protein folding is still one of the major problems in molecular biology.

As for any chemical reaction, a clear description of the folding of a protein would require the identification and structural characterization of each of the molecular species transiently populated during the process [1]; however, in the case of protein folding, experimental difficulties arise because of the intrinsic cooperativity of the process and the large number of weak interactions forming from the denatured state to the native state in a biologically relevant timescale [2].

In this context, the description of the folding mechanism of proteins populating partially folded intermediates is particularly valuable, as it may offer the opportunity to follow the evolution of structure formation. In this context, the BET (bromo-extra-terminal domain) bromodomains (BRDs) represent a useful experimental system not only because

of their limited molecular weight (about 100 amino acids) and structural simplicity, but also because their role in a variety of patho-physiological processes is becoming increasingly evident [3,4]. Recently, the second BRD of BRD2 (hereafter, BRD2(2)) has been highlighted as an essential node in the cellular response to SARS-CoV-2 infection [5,6].

BRDs are structural motifs that are known to recognize and bind to acetylated Lys residues in histones. The available structures of a variety of BRDs in the PDB database show that this domain consists of a helical bundle composed of four conserved α -helices (α Z, α A, α B, and α C, from the N- to the C-terminus of the domain) connected by loop regions of variable length, notably the ZA loop connecting helices α Z and α A and the BC loop connecting helices α B and α C [7] (Figure 1). These domains act as modulators of eukaryotic gene expression [7,8] by recognizing and binding to the N-terminal tails of histone proteins containing one or more acetyl-lysine residues (AcK). The specific recognition of the post-translationally modified AcK involves a set of highly conserved residues in the hydrophobic core of the domain [9]; however, it has been recently proposed that the highly flexible and less conserved ZA loop may additionally contribute to the binding mechanism [10–12].




Figure 1. The structure of BRD2(2) (PDB: 3ONI). The structure of the bromodomains is a four-helix bundle formed by four conserved α -helices α Z, α A, α B, and α C connected by loop regions (ZA and BC loops) of variable length. The hydrophobic binding pocket is located at the end of the bundle (on top of the structure represented here) and surrounded by residues located on the loops ZA and BC.

We recently described the kinetic folding mechanism of two BET bromodomains: the second BRD of BRD2 (BRD2(2)) and the first BRD of BRD4 (BRD4(1)), demonstrating in both cases the population of a transient obligatory intermediate by rapid mixing and temperature jump (un)folding experiments [13]. Here, we take a step further in elucidating the folding scenario of these domains by providing a structural characterization of the intermediate (I) and late transition state (TS2) of the BRD2(2) domain by Φ value analysis [14], as probed by the kinetic analysis of 25 site-directed mutants.

2. Results and Discussion

2.1. Urea-Induced Equilibrium Unfolding

Twenty-five site-directed mutants were designed and produced in order to perform the Φ value analysis on BRD2(2). The mutants were designed by following the accepted guide-

lines adopted in Φ value analysis [14–16] and characterized by equilibrium denaturation experiments. The thermodynamic stability of the different BRD2(2) mutants was measured by urea-induced equilibrium unfolding experiments [13] at a pH of 7.5 and 20 °C by monitoring the change of ellipticity at 222 nm by CD spectroscopy (Supplementary Figure S1). The reversible urea-induced denaturations monitored by far-UV CD of all the BRD mutants showed a sigmoidal dependence on denaturant concentration that could be fitted to a two-state model. The free energy of urea-induced unfolding, $\Delta G^{\text{H}_2\text{O}}$, of the mutants and that of the wild type were obtained by globally fitting the whole dataset with a shared m -value of 1.93 kcal/mol/M [13] (Table 1). The mutants clustered into three classes according to their thermodynamic stability with respect to the wild type ($\Delta\Delta G^{\text{H}_2\text{O}}$). Mutants showing limited $\Delta\Delta G^{\text{H}_2\text{O}}$ included some mutants of the helix αZ (I356V, A366G), the loop ZA (A367G, A378G, A380G, L381A, and L383A), and the mutants A411G in the loop connecting αA and αB , as well as A437G in the helix αC . The mutants L350A, L357A, L360V, and L361A, located on the helix αZ , and the mutants V399A and V418A, located respectively, on the helices αA and αB , showed higher $\Delta\Delta G^{\text{H}_2\text{O}}$ values, ranging from 2 to 4 kcal/mol. All of these positions involved residues located in the hydrophobic core of the protein, suggesting that the destabilizing effects of the mutations on the thermodynamic stability may be referred to an alteration in the core of the protein. Finally, most of the mutants located in the C-terminal region of the protein (T398S, A415G, A416G, L420A, V435A, V436A, A439G, and V445A), as well as A369G and V376A, showed an intermediate decrease in thermodynamic stability with $\Delta\Delta G^{\text{H}_2\text{O}}$ values of 1 to 2 kcal/mol.

Table 1. Thermodynamic stability of BRD2(2) wild type and mutants.

Protein	$\Delta G^{\text{H}_2\text{O}}$ (kcal/mol)	[Urea] _{0.5}
wild type	8.94 ± 0.06	4.63
L350A	6.93 ± 0.06	3.59
I356V	8.24 ± 0.09	4.27
L357A	5.16 ± 0.09	2.67
L360V	6.37 ± 0.08	3.30
L361A	6.09 ± 0.05	3.15
A366G	8.31 ± 0.08	4.30
A367G	8.19 ± 0.06	4.24
A369G	7.88 ± 0.10	4.08
V376A	7.37 ± 0.08	3.82
A378G	8.49 ± 0.07	4.40
A380G	8.75 ± 0.10	4.53
L381A	9.23 ± 0.09	4.78
L383A	8.50 ± 0.08	4.40
T398S	7.57 ± 0.07	3.92
V399A	6.69 ± 0.07	3.47
A411G	8.44 ± 0.05	4.37
A415G	7.60 ± 0.11	3.94
A416G	7.77 ± 0.10	4.02
V418A	5.44 ± 0.04	2.82
L420A	6.97 ± 0.08	3.61
V435A	7.31 ± 0.08	3.79
V436A	7.81 ± 0.10	4.05
A437G	8.56 ± 0.11	4.43
A439G	7.54 ± 0.12	3.91
V445A	8.00 ± 0.08	4.14

Urea-induced unfolding equilibrium data were obtained at 20 °C in 20 mM of Tris HCl, pH = 7.5, containing 0.2 M of NaCl and 200 μM of DTT by measuring circular dichroism ellipticity at 222 nm $[\theta]_{222}$. $\Delta G^{\text{H}_2\text{O}}$ values were obtained from Equation (2), [Urea]_{0.5} values were obtained from Equation (3). Data were globally fitted to a two-state model according to Equation (2), with the m -values shared between the datasets. Data are reported as the mean \pm SE of the fit.

2.2. Folding Kinetics

As recalled above, we previously demonstrated that the two BET-BRDs, BRD2(2) and BRD4(1), follow a three-state mechanism, involving an on-pathway folding intermediate (I) in the sub-millisecond time regime [13]. In the same work, on the basis of a parameter derived from the kinetic data, i.e., the β -Tanford values [16,17], we estimated that, in the case of BRD2(2), the intermediate is characterized by limited compactness and poor native-like characteristics.

Therefore, in order to map in more detail the structural features of the transient species along the folding pathway of the BRD2(2) domain at a residue level and to identify the interactions stabilizing the intermediate and the folding transition state, we subjected all of the mutants to (un)folding kinetic experiments.

The complete (un)folding kinetics data set (chevron plot) obtained for each single mutant versus wild type BRD2(2) is reported in Figure 2 (representative kinetic folding and unfolding time courses are shown in Supplementary Figure S2).




Figure 2. Chevron plots of BRD2(2) and its mutants. In the different panels the chevron plots of BRD2(2) wild type (in black) and its mutants (in red) are shown. All of the experiments were carried out in 50 mM of Tris HCl, pH = 7.5, 0.2 M of NaCl, and 2 mM of DTT. The data were globally fitted to a three-state folding mechanism, sharing the m-values.

Following the same approach we have used in the characterization of the folding mechanism of BRD2(2) [13], the complete dataset was globally fitted to a three-state folding mechanism with shared values of m (Equation (4) in Materials and Methods). The calculated folding and unfolding parameters, together with the Φ values associated with the intermediate (I) and late transition state (TS2), are listed in Table 2. The robustness of our analysis was revealed by the good agreement between the ΔG_{D-N} values obtained from equilibrium denaturations (Table 1) and (un)folding kinetics (Table 2).

Table 2. Kinetic parameters of BRD2(2) and its mutants (see Materials and Methods) with Φ values calculation.

	k_{I-N} (s ⁻¹)	k_{N-I} (s ⁻¹)	K_{D-I}	ΔG_{D-N} (kcal/mol)	$\Delta \Delta G_{D-N}$ (kcal/mol)	$\Delta \Delta G_{TS2-N}$ (kcal/mol)	$\Delta \Delta G_{D-I}$ (kcal/mol)	Φ (I)	Φ (TS2)
wild type	362 ± 32	$7.44 \times 10^{-4} \pm 4.61 \times 10^{-5}$	21 ± 2.7	9.37 ± 0.10					
L350A	118 ± 13	$4.13 \times 10^{-3} \pm 2.59 \times 10^{-4}$	21 ± 3.1	7.72 ± 0.11	1.65 ± 0.15	0.99 ± 0.05	0.01 ± 0.11	0.01 ± 0.11	0.40 ± 0.04
I356V	176 ± 21	$1.43 \times 10^{-3} \pm 1.01 \times 10^{-4}$	15 ± 2.5	8.36 ± 0.13	1.02 ± 0.16	0.38 ± 0.05	0.22 ± 0.12	0.22 ± 0.13	0.63 ± 0.13
L357A	32 ± 4.5	$1.30 \times 10^{-2} \pm 7.01 \times 10^{-4}$	6.7 ± 1.4	5.64 ± 0.14	3.73 ± 0.17	1.66 ± 0.05	0.67 ± 0.14	0.18 ± 0.04	0.55 ± 0.03
L360V	81 ± 14	$9.53 \times 10^{-3} \pm 5.93 \times 10^{-4}$	5.5 ± 1.4	6.24 ± 0.19	3.13 ± 0.21	1.48 ± 0.05	0.79 ± 0.17	0.25 ± 0.06	0.53 ± 0.04
L361A	200 ± 30	$1.71 \times 10^{-2} \pm 1.09 \times 10^{-3}$	7.8 ± 1.7	6.63 ± 0.16	2.75 ± 0.19	1.82 ± 0.05	0.58 ± 0.15	0.21 ± 0.06	0.34 ± 0.03
A366G	458 ± 54	$4.92 \times 10^{-3} \pm 3.46 \times 10^{-4}$	19 ± 3.1	8.33 ± 0.12	1.04 ± 0.16	1.10 ± 0.05	0.08 ± 0.12	0.08 ± 0.12	−0.05 ± 0.01
A367G	232 ± 26	$3.07 \times 10^{-3} \pm 2.18 \times 10^{-4}$	27 ± 3.5	8.43 ± 0.12	0.94 ± 0.16	0.82 ± 0.05	−0.14 ± 0.12	−0.15 ± 0.13	0.12 ± 0.02
A369G	340 ± 30	$6.22 \times 10^{-3} \pm 4.02 \times 10^{-4}$	20 ± 3.1	8.08 ± 0.12	1.30 ± 0.15	1.23 ± 0.05	0.03 ± 0.12	0.02 ± 0.08	0.05 ± 0.01
V376A	496 ± 42	$1.38 \times 10^{-2} \pm 9.25 \times 10^{-4}$	12 ± 2.3	7.54 ± 0.13	1.83 ± 0.16	1.69 ± 0.05	0.31 ± 0.13	0.17 ± 0.07	0.07 ± 0.01
A378G	319 ± 32	$2.97 \times 10^{-3} \pm 1.95 \times 10^{-4}$	30 ± 4.1	8.69 ± 0.11	0.68 ± 0.14	0.80 ± 0.05	−0.19 ± 0.11	−0.28 ± 0.17	−0.17 ± 0.04
A380G	502 ± 51	$1.63 \times 10^{-3} \pm 1.19 \times 10^{-4}$	12 ± 2.2	8.79 ± 0.13	0.58 ± 0.16	0.46 ± 0.06	0.32 ± 0.13	0.54 ^a ± 0.07	0.22 ^a ± 0.26
L381A	537 ± 56	$9.83 \times 10^{-4} \pm 7.35 \times 10^{-5}$	14 ± 2.4	9.19 ± 0.13	0.19 ± 0.16	0.16 ± 0.06	0.25 ± 0.12	1.36 ^a ± 0.12	0.13 ^a ± 1.28
L383A	461 ± 34	$3.57 \times 10^{-3} \pm 2.23 \times 10^{-4}$	12 ± 1.5	8.29 ± 0.10	1.08 ± 0.14	0.91 ± 0.05	0.31 ± 0.10	0.29 ± 0.05	0.16 ± 0.02
T398S	215 ± 27	$4.18 \times 10^{-3} \pm 2.83 \times 10^{-4}$	11 ± 2.2	7.71 ± 0.14	1.66 ± 0.17	1.00 ± 0.05	0.36 ± 0.13	0.21 ± 0.08	0.45 ± 0.05
V399A	114 ± 36	$2.37 \times 10^{-3} \pm 1.51 \times 10^{-4}$	1.9 ± 0.8	6.65 ± 0.11	2.72 ± 0.15	0.67 ± 0.05	1.38 ± 0.10	0.51 ± 0.05	0.75 ± 0.07
A411G	373 ± 30	$7.97 \times 10^{-4} \pm 5.64 \times 10^{-5}$	3.9 ± 0.7	8.37 ± 0.08	1.00 ± 0.12	0.04 [*] ± 0.05	0.97 ± 0.09	0.98 ± 0.15	0.96 ± 1.19
A415G	260 ± 24	$1.08 \times 10^{-3} \pm 7.43 \times 10^{-5}$	3.4 ± 0.7	7.91 ± 0.10	1.46 ± 0.14	0.22 ± 0.04	1.05 ± 0.11	0.72 ± 0.10	0.85 ± 0.16
A416G	237 ± 19	$1.32 \times 10^{-3} \pm 8.96 \times 10^{-5}$	3.4 ± 0.7	7.73 ± 0.10	1.64 ± 0.14	0.33 ± 0.05	1.06 ± 0.11	0.65 ± 0.09	0.80 ± 0.15
V418A	143 ± 13	$8.38 \times 10^{-3} \pm 3.05 \times 10^{-4}$	1.0 ± 0.4	5.63 ± 0.17	3.74 ± 0.19	1.40 ± 0.05	1.80 ± 0.17	0.48 ± 0.05	0.62 ± 0.04
L420A	348 ± 41	$1.93 \times 10^{-2} \pm 1.28 \times 10^{-3}$	17 ± 3.1	7.33 ± 0.13	2.04 ± 0.16	1.89 ± 0.05	0.12 ± 0.13	0.06 ± 0.06	0.07 ± 0.01
V435A	594 ± 56	$6.07 \times 10^{-3} \pm 4.14 \times 10^{-4}$	7.3 ± 1.6	7.82 ± 0.15	1.55 ± 0.18	1.22 ± 0.05	0.62 ± 0.14	0.40 ± 0.10	0.21 ± 0.03
V436A	479 ± 48	$4.31 \times 10^{-3} \pm 2.66 \times 10^{-4}$	9.2 ± 1.4	8.03 ± 0.11	1.35 ± 0.15	1.02 ± 0.05	0.49 ± 0.12	0.36 ± 0.09	0.24 ± 0.03
A437G	519 ± 35	$8.83 \times 10^{-4} \pm 6.38 \times 10^{-5}$	5.2 ± 1.2	8.67 ± 0.07	0.70 ± 0.12	0.10 ± 0.02	0.81 ± 0.10	1.16 ± 0.24	0.86 ± 0.17
A439G	436 ± 42	$4.60 \times 10^{-4} \pm 3.33 \times 10^{-5}$	3.2 ± 0.7	8.65 ± 0.11	0.72 ± 0.15	−0.28 ± 0.06	1.11 ± 0.11	1.54 ± 0.35	1.39 ± 0.39
V445A	527 ± 51	$5.21 \times 10^{-3} \pm 3.23 \times 10^{-4}$	11 ± 1.6	8.07 ± 0.11	1.30 ± 0.15	1.13 ± 0.05	0.39 ± 0.11	0.30 ± 0.09	0.13 ± 0.02

^a The mutant shows a $\Delta \Delta G_{D-N} < 0.6$ kcal/mol, preventing a reliable calculation of the Φ value. ^{*} The very low $\Delta \Delta G_{TS2-N}$ determines the high error on the Φ (TS2) value.

In accordance with the standard methodology [16], the calculated Φ values were divided into three groups (low: $\Phi < 0.3$; intermediate: $0.3 < \Phi < 0.7$; high: $\Phi > 0.7$) and mapped onto the native structure of BRD2(2). As shown in Figure 3a, the structural distribution of the Φ values indicated that the intermediate was characterized by a few native-like contacts identified by high Φ (I) values. Such a relatively small number of native-like interactions was in accordance with a non-compact partially folded state with scarce native-like characteristics, as hypothesized earlier on the basis of the low β -Tanford value [13]. The high Φ (I) values are located primarily in helix α B (A411, A415, A416), a region that represents the initial folding nucleus. As the number of native-like contacts was only marginally increased later in the process, it appears that the sequence of BRD2(2) was not optimized for efficient folding. Indeed, only two additional high Φ values were measured for the late transition state TS2 (A416 in helix α B and V399 in helix α A) (see Figure 3b). Interestingly, such a scenario, implying a rugged folding landscape, has been proposed earlier for another, unrelated, small four-helix bundle protein [18].

suggests the development of different nuclei, as predicted by a diffusion–collision folding mechanism [22]. Although the Bronsted plot for I and TS2 displayed an overall linear dependence, in the former case, dispersion of the data was more evident ($R = 0.47$ and 0.77 , respectively) and the slope was lower (0.25 and 0.6 , respectively), strengthening the hypothesis that the formation of the intermediate proceeds along a non-cooperative and rugged energy landscape, whereas a more cooperative process leads to the formation of the native-like transition state TS2. Inspection of Figure 4a shows that almost all of the positions with a higher value of $\Delta\Delta G_{D-I}$ than the overall trend (i.e., residues 399, 411, 418, and 439) are clustered in the hydrophobic core of the protein domain, whereas the residues with the lower values of $\Delta\Delta G_{D-I}$ (i.e., residues 350, 357, 367, and 378) are mainly located in the αZ helix and ZA loop. These results indicate that the stability of the intermediate does not rely on residues in the N-terminal part of the domain, but is mainly stabilized by a diffused nucleus involving a limited number of residues located in α -helices αA , αB , and αC in the C-terminal half of BRD2(2). On the contrary, the Bronsted plot for TS2 (Figure 4b) shows a better correlation, indicating that, as observed in other protein domains [23] and theoretically predicted [24], the late transition state TS2 is more native-like, representing a distorted version of the native state. Overall, these findings are in accordance with the distribution of the Φ values in the structure of BRD2(2) discussed above (Figure 3), and indicate that the intermediate is mainly stabilized by a small hydrophobic nucleus at the C-terminus of the domain and involves residues in the α -helices αA , αB , and αC .




Figure 4. Bronsted plots for intermediate (a) (squares) and transition state two (b) (dots). In (a) the residues above/below the general trend for $\Delta\Delta G_{D-I}$ (see text) are also highlighted. The R values are 0.47 and 0.77 , respectively, and the slope values are 0.25 and 0.6 , respectively.

3. Conclusions

Although the BRDs are protein domains that play crucial roles in many cellular processes, fundamental aspects, such as their folding mechanism, are still largely unexplored. The complete characterization of the folding of BRD2(2) by Φ value analysis provided in this work allowed us to obtain, for the first time in this protein class, structural information on both the intermediate I and transition state TS2. Moreover, by analyzing the contributions of native and non-native interactions at early and late stages of folding, we could depict a rugged folding landscape and hypothesize that the evolutionary pressure for maintaining the function of BRD2(2) may have decreased its folding efficiency. Future work will test this hypothesis by comparing the folding efficiency and binding properties of BRD2(2).

4. Materials and Methods

4.1. Site-Directed Mutagenesis

The constructs encoding the site-directed mutants of BRD2(2) were obtained using the gene encoding BRD2(2) wild type as a template to perform site-directed mutagenesis with

the QuickChange Lightning Site-Directed Mutagenesis kit (Agilent Technologies, Santa Clara, CA) according to the manufacturer's instructions. All mutations were confirmed by DNA sequencing analysis.

4.2. Protein Expression and Purification

The BRD2(2) wild type and all of the site-directed mutants were expressed in *E. coli* Rosetta cells. Bacterial cells were grown in an LB medium, containing 30 µg/mL of kanamycin at 37 °C until OD₆₀₀ = 0.6, and then protein expression was induced with 0.5 mM of IPTG. After induction, cells were grown at 18 °C overnight and then collected by centrifugation.

To purify the protein, the bacterial pellet was resuspended and treated as described previously [25]. The purity of the protein was analyzed through SDS-PAGE, and the structural integrity of the purified proteins was checked by circular dichroism (CD) spectra in the far- and near-UV region. Protein concentration was determined spectrophotometrically using a molar absorptivity coefficient (ϵ 280) corresponding to 15,930 M⁻¹cm⁻¹ for wild type and the other mutants, based on a molecular mass of 13,351.3 Da, and calculated according to Gill and von Hippel [26].

4.3. Equilibrium Experiments

Equilibrium unfolding experiments were carried out at 20 °C in 20 mM of Tris HCl, pH = 7.5, 0.2 M of NaCl, and 200 µM of DTT. CD measurements were carried out with a JASCO J-720 spectropolarimeter using a 0.2 cm cuvette. BRD2(2) and all of the site-directed mutants, at a constant concentration of 80 µg/mL, were incubated at 20 °C at increasing urea concentration (0–9.0 M). When equilibrium was reached, far-UV CD spectra were recorded. The reversibility of the BRD2(2) wild type and mutant unfolding was checked as described previously [13]. All equilibrium unfolding experiments were performed in triplicate. Urea-induced equilibrium unfolding transitions monitored by far-UV CD ellipticity changes was analyzed by fitting the baseline and transition region data to a two-state linear extrapolation model [27] according to:

$$\Delta G_{\text{unfolding}} = \Delta G_{\text{H}_2\text{O}}^{\text{H}_2\text{O}} + m[\text{Urea}] - RT \ln (K_{\text{unfolding}}) \quad (1)$$

where $\Delta G_{\text{unfolding}}$ is the free energy change for unfolding for a given denaturant concentration, $\Delta G_{\text{H}_2\text{O}}^{\text{H}_2\text{O}}$ is the free energy change for unfolding in the absence of denaturant, m is a slope term which quantifies the change in $\Delta G_{\text{unfolding}}$ per unit concentration of denaturant, R is the gas constant, T is the temperature, and $K_{\text{unfolding}}$ is the equilibrium constant for unfolding. The model expresses the signal as a function of denaturant concentration:

$$y_i = y_N + s_N[X]_i + (y_U + s_U[X]_i) * \exp[(-\Delta G_{\text{H}_2\text{O}}^{\text{H}_2\text{O}} - m[X]_i)/RT] / (1 + \exp[(-\Delta G_{\text{H}_2\text{O}}^{\text{H}_2\text{O}} - m[X]_i)/RT]) \quad (2)$$

where y_i is the observed signal, y_U and y_N are the baseline intercepts for unfolded and native protein, s_U and s_N are the baseline slopes for the unfolded and native protein, $[X]_i$ is the denaturant concentration after the i th addition, $\Delta G_{\text{H}_2\text{O}}^{\text{H}_2\text{O}}$ is the extrapolated free energy of unfolding in the absence of denaturant, and m is the slope in a $\Delta G_{\text{unfolding}}$ versus $[X]$ plot. Data were globally fitted with the m -values shared between the datasets; all other parameters were not constrained.

The denaturant concentration at the midpoint of the transition, $[\text{Urea}]_{0.5}$, according to Equation (2), is calculated as:

$$[\text{Urea}]_{0.5} = \Delta G_{\text{H}_2\text{O}}^{\text{H}_2\text{O}} / m \quad (3)$$

All unfolding transition data were fitted using GraphPad Prism 5. Data were normalized between 0 and 100%, where 0 corresponds to the molar ellipticity at 222 nm of the native protein, the smallest value (at 0 M urea), and 100 corresponds to the molar ellipticity at 222 nm of the unfolded protein, the largest value (at 9 M urea).

4.4. Kinetic Experiments

Unfolding and refolding kinetics experiments were performed using an SX-18 stopped-flow apparatus (Applied Photophysics, Leatherhead, UK). The protein samples were excited at 280 nm, and the fluorescence emission was measured using a 320 nm cutoff glass filter. The final concentration of the protein was typically 3 μ M. At least five individual traces were acquired and then averaged for each experiment. All of the averages were satisfactorily fitted with a single exponential equation. Experiments were conducted in a buffer of 50 mM of Tris HCl, pH = 7.5, 0.2 M of NaCl, and 2 mM of DTT, as well as different concentrations of urea, ranging from 0.7 M to 8.1 M, at 20 °C.

The semilogarithmic plot (chevron plot) of each mutant was fitted on the basis of a three-state folding scheme with an on-pathway intermediate as previously reported [13,28] by using the following equation:

$$Y_{(X)} = \log((k_{I-N} * \exp(-m_{I-N} * X/RT))/(1 + (1/K_{D-I} * \exp(m_{D-I} * X/RT)) + k_{N-I} * \exp(m_{N-I} * X/RT)) \quad (4)$$

where $Y_{(X)}$ is the observed signal at the given denaturant concentration (X) and k_{I-N} and k_{N-I} represent the microscopic rate constants for the folding transition from the intermediate state (I) to the native state (N) and the unfolding from the native state (N) to the intermediate state (I) in the absence of denaturant, respectively; K_{D-I} is the equilibrium constant between the denatured (D) state and the I state, while m_{I-N} , m_{N-I} , and m_{D-I} are the denaturant dependence of the relative rate constants, R is universal gas constant, and T is the temperature expressed in Kelvin. During the global fitting procedure, the m -value was shared in the dataset to increase fitting accuracy. Data analysis was performed on GraphPad Prism software (GraphPad Software, Inc., San Diego, CA, USA).

The thermodynamic stability (ΔG_{D-N}) for each mutant was evaluated from the equilibrium/kinetic constants summing the $\Delta G_{D-I} + \Delta G_{I-N}$ stability as follow:

$$\Delta G_{D-N} = \Delta G_{D-I} + \Delta G_{I-N} = (-RT \ln (1/K_{D-I})) + (-RT \ln (k_{I-N}/k_{N-I})) \quad (5)$$

The Φ values related to the intermediate state ($\Phi(I)$) and the transition state 2 ($\Phi(TS2)$) for each mutant were calculated as follows:

$$\Phi(TS2) = 1 - (\Delta\Delta G_{TS2-N}/\Delta\Delta G_{D-N}) \quad (6)$$

$$\Phi(I) = \Delta\Delta G_{D-I}/\Delta\Delta G_{D-N} \quad (7)$$

where:

$$\Delta\Delta G_{D-N} = \Delta G_{D-N}^{WT} - \Delta G_{D-N}^{mut} \quad (8)$$

$$\Delta\Delta G_{TS2-N} = \Delta G_{TS2-N}^{WT} - \Delta G_{TS2-N}^{mut} = RT \ln (k_{N-I}^{mut}/k_{N-I}^{WT}) \quad (9)$$

$$\Delta\Delta G_{D-I} = \Delta G_{D-I}^{WT} - \Delta G_{D-I}^{mut} = RT \ln (k_{D-I}^{mut}/k_{D-I}^{WT}) \quad (10)$$

Supplementary Materials: The following figures are available online at <https://www.mdpi.com/article/10.3390/ijms22115953/s1>. Figure S1: Urea-induced equilibrium unfolding of BRD2(2) wild type and mutants. Figure S2: Representative kinetic traces of BRD2(2) A367G mutant for unfolding (a) ([Urea] = 8.1 M) and refolding (b) ([Urea] = 0.7 M) together with their relative residuals plot.

Author Contributions: Conceptualization, C.T.-A., R.C., and V.C.; methodology, L.N., M.P., D.S., and A.P.; software, L.N., M.P., D.S., R.C., V.C., and C.T.-A.; validation, L.N., M.P., D.S., A.P., R.C., V.C., and C.T.-A.; formal analysis, C.T.-A., M.P., R.C., and V.C.; investigation, C.T.-A., R.C., and V.C.; resources, C.T.-A., R.C., and V.C.; data curation, C.T.-A., M.P., R.C., and V.C.; writing—original draft preparation, C.T.-A. and M.P.; writing—review and editing, C.T.-A., L.N., M.P., D.S., R.C., and V.C.; visualization, A.P.; supervision, C.T.-A., R.C., and V.C.; project administration, C.T.-A., R.C., and V.C.; funding acquisition, C.T.-A., R.C., and V.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by MIUR Progetti di Ricerca di Rilevante Interesse Nazionale (PRIN) 2017—n. 201744NR8S.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Acknowledgments: This work has been supported by a project funded by the MIUR Progetti di Ricerca di Rilevante Interesse Nazionale (PRIN) 2017—n. 201744NR8S.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Gianni, S.; Ivarsson, Y.; Jemth, P.; Brunori, M.; Travaglini-Allocatelli, C. Identification and characterization of protein folding intermediates. *Biophys. Chem.* **2007**, *128*, 105–113. [[CrossRef](#)]
2. Dill, K.A.; Maccallum, J.L. The Protein-Folding Problem, 50 Years On. *Science* **2012**, *338*, 1042–1046. [[CrossRef](#)]
3. Dawson, M.A.; Kouzarides, T.; Huntly, B.J.P. Targeting Epigenetic Readers in Cancer. *N. Engl. J. Med.* **2012**, *367*, 647–657. [[CrossRef](#)]
4. Muller, S.; Filippakopoulos, P.; Knapp, S. Bromodomains as therapeutic targets. *Expert Rev. Mol. Med.* **2011**, *13*, e29. [[CrossRef](#)]
5. Qiao, Y.; Wang, X.-M.; Mannan, R.; Pitchaiya, S.; Zhang, Y.; Wotring, J.W.; Xiao, L.; Robinson, D.R.; Wu, Y.-M.; Tien, J.C.-Y.; et al. Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2. *Proc. Natl. Acad. Sci. USA* **2021**, *118*, e2021450118. [[CrossRef](#)] [[PubMed](#)]
6. Gordon, D.E.; Jang, G.M.; Bouhaddou, M.; Xu, J.; Obernier, K.; White, K.M.; O'Meara, M.J.; Rezelj, V.V.; Guo, J.Z.; Swaney, D.L.; et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature* **2020**, *583*, 459–468. [[CrossRef](#)] [[PubMed](#)]
7. Ferri, E.; Petosa, C.; McKenna, C.E. Bromodomains: Structure, function and pharmacology of inhibition. *Biochem. Pharmacol.* **2016**, *106*, 1–18. [[CrossRef](#)] [[PubMed](#)]
8. Josling, G.A.; Selvarajah, S.A.; Petter, M.; Duffy, M.F. The Role of Bromodomain Proteins in Regulating Gene Expression. *Genes* **2012**, *3*, 320–343. [[CrossRef](#)]
9. Zeng, L.; Zhang, Q.; Gerona-Navarro, G.; Moshkina, N.; Zhou, M.-M. Structural Basis of Site-Specific Histone Recognition by the Bromodomains of Human Coactivators PCAF and CBP/p300. *Structure* **2008**, *16*, 643–652. [[CrossRef](#)] [[PubMed](#)]
10. Mujtaba, S.; Zeng, L.; Zhou, M.-M. Structure and acetyl-lysine recognition of the bromodomain. *Oncogene* **2007**, *26*, 5521–5527. [[CrossRef](#)]
11. Magno, A.; Steiner, S.; Cafilisch, A. Mechanism and Kinetics of Acetyl-Lysine Binding to Bromodomains. *J. Chem. Theory Comput.* **2013**, *9*, 4225–4232. [[CrossRef](#)] [[PubMed](#)]
12. Langini, C.; Cafilisch, A.; Vitalis, A. The ATAD2 Bromodomain Binds Different Acetylation Marks on the Histone H4 in Similar Fuzzy Complexes. *J. Biol. Chem.* **2017**, *292*, 16734–16745. [[CrossRef](#)]
13. Petrosino, M.; Bonetti, D.; Pasquo, A.; Lori, L.; Chiaraluze, R.; Consalvi, V.; Travaglini-Allocatelli, C. Unveiling the folding mechanism of the Bromodomains. *Biochem. Biophys. Rep.* **2017**, *11*, 99–104. [[CrossRef](#)]
14. Fersht, A.R.; Sato, S. Φ value analysis and the nature of protein-folding transition states. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 7976–7981. [[CrossRef](#)] [[PubMed](#)]
15. Serrano, L.; Matouschek, A.; Fersht, A.R. The folding of an enzyme: III. Structure of the transition state for unfolding of barnase analysed by a protein engineering procedure. *J. Mol. Biol.* **1992**, *224*, 805–818. [[CrossRef](#)]
16. Fersht, A. *Structure and Mechanism in Protein Science: A Guide to Enzyme Catalysis and Protein Folding*; Freeman WH and Co.: New York, NY, USA, 1999.
17. Tanford, C. Protein denaturation. C. Theoretical models for the mechanism of denaturation. *Adv. Protein. Chem.* **1970**, *24*, 1–95.
18. Friel, C.T.; Smith, D.A.; Vendruscolo, M.; Gsponer, J.; Radford, S.E. The mechanism of folding of Im7 reveals competition between functional and kinetic evolutionary constraints. *Nat. Struct. Mol. Biol.* **2009**, *16*, 318–324. [[CrossRef](#)]
19. Baxa, M.C.; Yu, W.; Adhikari, A.N.; Ge, L.; Xia, Z.; Zhou, R.; Freed, K.F.; Sosnick, T.R. Even with nonnative interactions, the updated folding transition states of the homologs Proteins G & L are extensive and similar. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 8302–8307. [[CrossRef](#)]
20. Gianni, S.; Freiberger, M.I.; Jemth, P.; Ferreira, D.U.; Wolynes, P.G.; Fuxreiter, M. Fuzziness and Frustration in the Energy Landscape of Protein Folding, Function, and Assembly. *Accounts Chem. Res.* **2021**, *54*, 1251–1259. [[CrossRef](#)] [[PubMed](#)]
21. Xu, M.; Unzue, A.; Dong, J.; Spiliotopoulos, D.; Nevado, C.; Cafilisch, A. Discovery of CREBBP Bromodomain Inhibitors by High-Throughput Docking and Hit Optimization Guided by Molecular Dynamics. *J. Med. Chem.* **2015**, *59*, 1340–1349. [[CrossRef](#)]
22. Karplus, M.; Weaver, D.L. Protein folding dynamics: The diffusion-collision model and experimental data. *Protein Sci.* **1994**, *3*, 650–668. [[CrossRef](#)]
23. Gianni, S.; Geierhaas, C.D.; Calosci, N.; Jemth, P.; Vuister, G.; Travaglini-Allocatelli, C.; Vendruscolo, M.; Brunori, M. A PDZ domain recapitulates a unifying mechanism for protein folding. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 128–133. [[CrossRef](#)]
24. Onuchic, J.N.; Wolynes, P.G. Theory of protein folding. *Curr. Opin. Struct. Biol.* **2004**, *14*, 70–75. [[CrossRef](#)] [[PubMed](#)]

25. Lori, L.; Pasquo, A.; Lori, C.; Petrosino, M.; Chiaraluce, R.; Tallant, C.; Knapp, S.; Consalvi, V. Effect of BET Missense Mutations on Bromodomain Function, Inhibitor Binding and Stability. *PLoS ONE* **2016**, *11*, e0159180. [[CrossRef](#)] [[PubMed](#)]
26. Gill, S.C.; von Hippel, P.H. Calculation of protein extinction coefficients from amino acid sequence data. *Anal. Biochem.* **1989**, *182*, 319–326. [[CrossRef](#)]
27. Santoro, M.M.; Bolen, D.W. Unfolding Free Energy Changes Determined by the Linear Extrapolation Method. 1. Un-folding of Phenylmethanesulfonyl. Alpha.-Chymotrypsin Using Different Denaturants. *Biochemistry* **1988**, *27*, 8063–8068. [[CrossRef](#)] [[PubMed](#)]
28. Parker, M.J.; Spencer, J.; Clarke, A.R. An Integrated Kinetic Analysis of Intermediates and Transition States in Protein Folding Reactions. *J. Mol. Biol.* **1995**, *253*, 771–786. [[CrossRef](#)] [[PubMed](#)]